Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2024 · 50 positions · Total reported value $2.41B · Top-10 concentration 66.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 22.7% · 6 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2024 13F filing, Frazier Life Sciences Management, L.P. disclosed 50 equity positions with a combined reported value of $2.41B. The filing implies a focused portfolio: its ten largest positions account for 66.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2024 were NAMS ($409.05M), MIRM ($271.69M), VRNA ($157.15M). By sector, the heaviest allocations are Health Care 87.6%, Materials 0.3%. Versus the prior quarter, allocation shifted toward Other (+2.1pp) and away from Health Care (-2.3pp).

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 84% of names.

The largest new positions opened in Q4 2024 were PLRX ($14.76M), PVLA ($7.85M), ELDN ($4.85M).

Of the 3 positions fully exited versus the prior quarter, the largest were TYRA ($17.19M), PBYI ($7.81M), PEPG ($6.01M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • PLRX PLIANT THERAPEUTICS INC · $14.76M
  • PVLA PALVELLA THERAPEUTICS INC NE · $7.85M
  • ELDN ELEDON PHARMACEUTICALS INC · $4.85M

Fully Exited (vs previous quarter)

  • TYRA TYRA BIOSCIENCES INCORPORATED · prev qtr: $17.19M
  • PBYI PUMA BIOTECHNOLOGY INC · prev qtr: $7.81M
  • PEPG PEPGEN INC · prev qtr: $6.01M
  • NUVB NUVATION BIO INC · prev qtr: $2.79M
  • ACRS ACLARIS THERAPEUTICS INC · prev qtr: $304.03K · history
  • PIRS PIERIS PHARMACEUTICALS INC · prev qtr: $266.87K

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 41 positions · $4.59B reported value (Q2 2026)
  • Top 10 holdings = 73.6% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
  • Average position size: $112.00M

Sector Tilt

  • Health Care 99.8%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
  • 26 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 87.6%
Materials 0.3%
Other 12.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 15.92M $409.05M 16.98%
16.98%
Add
2 6.57M $271.69M 11.28%
11.28%
Hold
3 3.38M $157.15M 6.52%
6.52%
Hold
4 788.46K $123.52M 5.13%
5.13%
Reduce
5 8.79M $122.38M 5.08%
5.08%
Hold
6 1.75M $111.26M 4.62%
4.62%
Hold
7 5.99M $110.31M 4.58%
4.58%
Hold
8 1.87M $104.67M 4.34%
4.34%
Reduce
9 3.80M $104.28M 4.33%
4.33%
Add
10 1.59M $87.90M 3.65%
3.65%
Hold
11 10.11M $82.09M 3.41%
3.41%
Hold
12 19.39M $48.67M 2.02%
2.02%
Hold
13 539.40K $44.16M 1.83%
1.83%
Reduce
14 10.66M $43.94M 1.82%
1.82%
Add
15 997.46K $43.63M 1.81%
1.81%
Hold
16 4.89M $41.40M 1.72%
1.72%
Add
17 1.07M $35.15M 1.46%
1.46%
Add
18 1.27M $33.94M 1.41%
1.41%
Reduce
19 699.16K $31.43M 1.30%
1.30%
Reduce
20 3.89M $31.38M 1.30%
1.30%
Reduce
21 658.72K $27.71M 1.15%
1.15%
Add
22 8.66M $26.59M 1.10%
1.10%
Add
23 770.00K $22.08M 0.92%
0.92%
Hold
24 10.62M $21.98M 0.91%
0.91%
Hold
25 1.57M $20.84M 0.86%
0.86%
Reduce
26 1.48M $18.59M 0.77%
0.77%
Hold
27 133.33K $18.36M 0.76%
0.76%
Hold
28 5.10M $17.84M 0.74%
0.74%
Hold
29 601.13K $17.29M 0.72%
0.72%
Add
30 373.10K $15.69M 0.65%
0.65%
Hold
31 2.15M $15.27M 0.63%
0.63%
Add
32 1.12M $14.76M 0.61%
0.61%
New
33 1.95M $12.05M 0.50%
0.50%
Add
34 583.33K $11.31M 0.47%
0.47%
Add
35 4.62M $10.86M 0.45%
0.45%
Hold
36 3.18M $10.32M 0.43%
0.43%
Add
37 689.65K $8.74M 0.36%
0.36%
Hold
38 470.34K $8.63M 0.36%
0.36%
Hold
39 1.15M $7.90M 0.33%
0.33%
Hold
40 653.89K $7.85M 0.33%
0.33%
New
41 1.00M $7.82M 0.33%
0.33%
Hold
42 936.58K $7.31M 0.30%
0.30%
Hold
43 500.33K $7.13M 0.30%
0.30%
Hold
44 955.51K $6.29M 0.26%
0.26%
Reduce
45 2.87M $6.11M 0.25%
0.25%
Hold
46 285.33K $5.47M 0.23%
0.23%
Hold
47 1.07M $4.99M 0.21%
0.21%
Hold
48 1.18M $4.85M 0.20%
0.20%
New
49 5.99M $3.37M 0.14%
0.14%
Hold
50 108.76K $3.21M 0.13%
0.13%
Hold

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2024-Q4?

In its 2024-Q4 13F filing, Frazier Life Sciences Management, L.P. reported 50 equity positions worth $2.41B in aggregate; its largest disclosed positions were NAMS ($409.05M), MIRM ($271.69M), VRNA ($157.15M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $2.41B of long equity holdings across 50 positions as of 2024-Q4. Top-10 holdings account for 66.5% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →